158 related articles for article (PubMed ID: 11842395)
1. Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma.
Warren TL; Weiner GJ
Semin Oncol; 2002 Feb; 29(1 Suppl 2):93-7. PubMed ID: 11842395
[TBL] [Abstract][Full Text] [Related]
2. Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma.
Warren TL; Weiner GJ
Semin Oncol; 2002 Feb; 29(1S2):93-97. PubMed ID: 28140098
[TBL] [Abstract][Full Text] [Related]
3. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma.
Warren TL; Dahle CE; Weiner GJ
Clin Lymphoma; 2000 Jun; 1(1):57-61. PubMed ID: 11707814
[TBL] [Abstract][Full Text] [Related]
4. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma.
Wooldridge JE; Ballas Z; Krieg AM; Weiner GJ
Blood; 1997 Apr; 89(8):2994-8. PubMed ID: 9108420
[TBL] [Abstract][Full Text] [Related]
5. CpG oligodeoxynucleotide-based therapy of lymphoid malignancies.
Weiner GJ
Adv Drug Deliv Rev; 2009 Mar; 61(3):263-7. PubMed ID: 19168102
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
7. Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer.
Jahrsdörfer B; Weiner GJ
Semin Oncol; 2003 Aug; 30(4):476-82. PubMed ID: 12939716
[TBL] [Abstract][Full Text] [Related]
8. CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
Hiramatsu K; Serada S; Kobiyama K; Nakagawa S; Morimoto A; Matsuzaki S; Ueda Y; Fujimoto M; Yoshino K; Ishii KJ; Enomoto T; Kimura T; Naka T
Cancer Sci; 2015 Oct; 106(10):1474-8. PubMed ID: 26498112
[TBL] [Abstract][Full Text] [Related]
9. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
10. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
[TBL] [Abstract][Full Text] [Related]
11. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
12. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor.
Liu HM; Newbrough SE; Bhatia SK; Dahle CE; Krieg AM; Weiner GJ
Blood; 1998 Nov; 92(10):3730-6. PubMed ID: 9808567
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody.
Chen W; Yu Y; Shao C; Zhang M; Wang W; Zhang L; Cao X
Immunol Lett; 2001 May; 77(1):17-23. PubMed ID: 11348665
[TBL] [Abstract][Full Text] [Related]
14. CpG ODN enhances the efficacy of rituximab in non-Hodgkin lymphoma.
Buhé V; Guerrier T; Youinou P; Berthou C; Loisel S
Ann N Y Acad Sci; 2009 Sep; 1173():858-64. PubMed ID: 19758238
[TBL] [Abstract][Full Text] [Related]
15. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
[TBL] [Abstract][Full Text] [Related]
16. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
Weiner GJ
J Leukoc Biol; 2000 Oct; 68(4):455-63. PubMed ID: 11037965
[TBL] [Abstract][Full Text] [Related]
17. Rituximab: mechanism of action and resistance.
Maloney DG; Smith B; Rose A
Semin Oncol; 2002 Feb; 29(1 Suppl 2):2-9. PubMed ID: 11842383
[TBL] [Abstract][Full Text] [Related]
18. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs.
Ballas ZK; Krieg AM; Warren T; Rasmussen W; Davis HL; Waldschmidt M; Weiner GJ
J Immunol; 2001 Nov; 167(9):4878-86. PubMed ID: 11673492
[TBL] [Abstract][Full Text] [Related]
19. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization.
Weiner GJ; Liu HM; Wooldridge JE; Dahle CE; Krieg AM
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10833-7. PubMed ID: 9380720
[TBL] [Abstract][Full Text] [Related]
20. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens.
Jahrsdörfer B; Hartmann G; Racila E; Jackson W; Mühlenhoff L; Meinhardt G; Endres S; Link BK; Krieg AM; Weiner GJ
J Leukoc Biol; 2001 Jan; 69(1):81-8. PubMed ID: 11200072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
